TrialJournal for immunotherapy of cancer2025

Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.

Wanpeng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.